Protocol Ledger

NCT06619860 · Phase II · RECRUITING

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Interventional Phase II clinical trial protocol NCT06619860 sponsored by Vertex Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-18 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06619860
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06619860
Protocol FieldVerified Registry Value
NCT IdentifierNCT06619860
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2024-10-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06619860
Hospital Research SiteLocationSite Profile
Atlanta Center for Medical ResearchAtlanta, GAOpen Hospital Dossier ->
Velocity Clinical Research (Meridian)Meridian, IDOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI